Double-Blind, Randomised Study of Fosinopril vs Nifedipine SR in the Treatment of Mild-to-Moderate Hypertension in Elderly Patients

1991 ◽  
Vol 3 (S4) ◽  
pp. 45-53 ◽  
Author(s):  
Jacques Clementy
Keyword(s):  
Elderly Patients ◽  
Moderate Hypertension ◽  
Double Blind ◽  
Randomised Study

A Comparison of Atenolol and Long-Acting Trimazosin in Mild to Moderate Essential Hypertension

1985 ◽  
Vol 30 (2) ◽  
pp. 106-110 ◽  
Author(s):  
D. J. Webb ◽  
M. J. Hutcheson ◽  
M. P. Robertson ◽  
G. D. Murray ◽  
A. R. Lorimer ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Moderate Hypertension ◽  
Diastolic Pressure ◽  
Substantial Reduction ◽  
Density Lipoprotein ◽  
Double Blind ◽  
Randomised Study ◽  
Lipoprotein Concentration ◽  
Long Acting

In a 12-week double-blind randomised study the efficacy of atenolol and a new longer-acting formulation of trimazosin were compared when given once daily in patients with mild to moderate hypertension. Two parallel groups, each consisting of 18 patients, were studied. At randomisation the two groups were well matched for age and sex distribution. They were also well matched for blood pressure, pulse rate and body weight; these latter measurements were recorded at regular intervals during the 12 weeks of study. Atenolol produced substantial reduction in both systolic and diastolic blood pressure, and in heart rate, during 12 weeks of treatment. This therapeutic effect was maintained until the next dose after 24 hours. Trimazosin, by comparison, failed to reduce either systolic or diastolic pressure, or to alter heart rate. Side effects were minor with both agents and compliance with treatment was good. Atenolol caused significant elevation of plasma concentration of triglyceride, with reduction in high density lipoprotein concentration when compared with trimazosin. In conclusion, atenolol was confirmed as an effective agent for the treatment of mild to moderate hypertension. By comparison trimazosin in the longer-acting formulation was ineffective in this study. However, trimazosin may still find a place in treatment if used at higher dose.

Comparative Evaluation of Enalapril and Hydrochlorothiazide in Elderly Patients with Mild to Moderate Hypertension

1988 ◽  
Vol 22 (9) ◽  
pp. 680-684 ◽  
Author(s):  
John G. Gums ◽  
Larry M. Lopez ◽  
Gary P. Quay ◽  
Gerald H. Stein ◽  
Dean L. McCarley
Keyword(s):  
Combination Therapy ◽  
Elderly Patients ◽  
Moderate Hypertension ◽  
Enzyme Inhibitor ◽  
Double Blind ◽  
Elderly Males ◽  
Elderly Hypertensive ◽  
To Receive ◽  
Single Blind ◽  
Enalapril Group

Initial treatment of elderly hypertensive patients with an angiotensin-converting enzyme inhibitor is currently discouraged due to such patients' typical low-renin profile. To validate this principle, we studied 38 elderly males (aged ≥ 65 years) with mild to moderate hypertension, comparing hemodynamic responses to and subjective impressions of enalapril or hydrochlorothiazide (HCTZ). After gradual withdrawal of existing antihypertensive therapy and a four-week, single-blind placebo period, each patient was randomized in a double-blind fashion to receive either enalapril 10-20 mg/d or HCTZ 12.5-25 mg/d for two to four weeks. Combination therapy with both agents was employed if either alone failed to reduce seated diastolic BP to ≤ 90 mm Hg. Equivalent proportions of patients receiving enalapril or HCTZ (8 of 19 and 10 of 19, respectively; p = ns) responded with significant reductions in systolic and diastolic BP in seated and standing positions. Combination therapy was most effective in patients receiving HCTZ prior to enalapril. In patients receiving enalapril before HCTZ, BP changes were minimal. No adverse effects were observed in the enalapril group but occurred in an equivalent fraction of patients in the other groups (4 of 10 HCTZ alone, 6 of 20 enalapril + HCTZ; p = ns). We conclude that enalapril may be considered a reasonable monotherapeutic antihypertensive agent in some elderly patients. Combination with HCTZ is beneficial in patients who fail to respond adequately to HCTZ alone.

ADMINISTRATION OF MUCOLYTIC SOLUTION BEFORE UPPER ENDOSCOPY – A DOUBLE-BLIND, RANDOMISED STUDY

2018 ◽  
Author(s):  
M Hanousek ◽  
P Falt ◽  
B Pipek ◽  
M Stepan ◽  
P Fojtik ◽  
...  
Keyword(s):  
Upper Endoscopy ◽  
Double Blind ◽  
Randomised Study

Pharmacokinetics and Tolerability of Factor XIII Concentrates Prepared from Human Placenta or Plasma: a Crossover Randomised Study

1995 ◽  
Vol 74 (02) ◽  
pp. 622-625 ◽  
Author(s):  
H H Brackmann ◽  
R Egbring ◽  
A Ferster ◽  
P Fondu ◽  
J M Girardel ◽  
...  
Keyword(s):  
Factor Xiii ◽  
Bleeding Events ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Randomised Study ◽  
The Mean ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study ◽  
Fxiii Activity ◽  
Observation Period

SummaryThe pharmacokinetics and tolerability of factor XIII (FXIII) from plasma were compared with those of FXIII from placenta in a randomised, double-blind, crossover study involving 13 patients with congenital FXIII deficiency. Both FXIII activity and FXIII antigen were monitored. No difference was seen in the mean half-lives of the two preparations (9.3 days and 9.1 days for plasma and placenta FXIII activity, respectively). Response was similar for both preparations, but was slightly greater for FXIII from plasma.Similar results were found for recovery (65% vs 60%). The area under the data completed by extrapolation was significantly higher for FXIII from plasma. No differences between preparations in terms of efficacy or tolerability were observed. It can be concluded that treatment with FXIII concentrate from plasma is as efficient as with FXIII concentrate from placenta in terms of recovery and half-life. Both preparations were equivalent in terms of safety during the observation period. With the administration of monthly injections of approximately 30 U/kg serious bleeding events were prevented and no other serious adverse events occurred.

Sign in / Sign up

Export Citation Format

Share Document